Federal agents can buy stock in a hemp company, but they cannot touch marijuana. That is the core finding of a newly declassified FBI policy memo, originally written in 2022, that the agency released publicly last week without explanation.

The document draws a hard line between hemp and marijuana that tracks federal law almost exactly, then adds several restrictions that go beyond what the law technically requires. For anyone in the cannabis industry trying to read the regulatory environment, the memo offers a clear window into how the federal government still treats these two plants as fundamentally different, regardless of what a dozen-plus state markets have built around the flower.

The memo prohibits FBI employees from investing in any company that cultivates, processes, or distributes marijuana, full stop. The prohibition applies regardless of whether marijuana is legal in the state where that company operates. So an agent living in California, where adult use has been legal since 2016, cannot legally hold stock in a licensed Humboldt cultivator. Cannot consult for a dispensary chain. Cannot even volunteer at a cannabis nonprofit if that organization touches the plant.

Hemp is treated differently, and the memo spells out the reason directly: the 2018 Farm Bill federally legalized hemp and hemp-derived cannabinoids, including CBD, setting the threshold at 0.3 percent THC by dry weight. Under the policy, agents can invest “without restriction” in companies with a financial interest in the CBD industry, provided that interest does not involve products exceeding that 0.3 percent threshold and does not involve companies that promote marijuana for medical or recreational purposes.

That second condition is where the memo gets specific in ways that will matter to anyone selling hemp products.

The document states that a product “depicting a marijuana leaf on its label is considered promotion of marijuana” and therefore off-limits for agent investment. The guidance acknowledges this is a facts-and-circumstances test, but the cannabis leaf example is unambiguous. A hemp flower company whose packaging leans into legacy cannabis aesthetics, using leaf imagery or strain-culture branding, could disqualify itself from the investment-permissible category under this reading.

That has practical implications beyond the FBI’s own workforce. When federal agencies define “promotes marijuana” broadly enough to include a botanical illustration, it signals a posture that affects how regulators and courts might interpret similar language in other contexts. The DEA, the FDA, and state agencies with federal funding agreements all operate within frameworks that make these definitional choices consequential.

The employment restrictions in the memo are even stricter than the investment rules. FBI workers are barred from any outside employment or volunteer activity with any company cultivating, processing, or distributing marijuana. The prohibition extends to foreign jurisdictions where marijuana may be fully legal at the national level. An agent cannot go work a harvest in Canada on vacation time.

For hemp and CBD businesses, employees who want to work or volunteer with those companies need prior approval through a specific internal reporting tool. Approving authorities review those requests case by case and must deny any that could “create an appearance of violating the law or violating ethical standards.” That appearance standard gives reviewers wide discretion to say no even when the underlying activity is technically legal.

The memo was written in 2022 and classified for reasons the agency has not disclosed. The FBI also has not explained why it chose to release the document now, in early 2026. The timing lands in the middle of an administration that has shown little interest in advancing marijuana reform at the federal level, though the hemp market has continued to expand under the same federal framework that made it possible.

From the perspective of someone who spent years farming on the North Coast before licensing became the job, the memo captures something real about where the federal government still stands. The distinction between hemp and marijuana is legally coherent given current statute, but it produces outcomes that look strange from ground level. A craft cultivator in Trinity County running a compliant operation under a California A-type license is doing something that a sitting FBI agent is categorically forbidden from investing in. That same agent could, in theory, hold stock in a CBD beverage company operating out of Colorado, provided the label does not have a leaf on it.

The legal architecture here is not the memo’s fault. It reflects what Congress has and has not done. But the document makes visible how completely the federal prohibition still structures life for people inside the government, even as the cannabis market around them has become a multi-billion dollar licensed industry with its own commodity exchanges, appellate case law, and workforce.

For hemp operators, the takeaway is practical. If you want to be on the right side of a federal appearance-of-compliance test, keep the leaf off the label. For marijuana operators, there is no version of the memo that helps you. The line is where it has always been.